{"id":"https://openalex.org/W4301397367","doi":"https://doi.org/10.1016/j.htct.2022.09.1188","title":"Treatment of Mantle Cell Lymphoma in Transplant Non-Eligible Patients","display_name":"Treatment of Mantle Cell Lymphoma in Transplant Non-Eligible Patients","publication_year":2022,"publication_date":"2022-10-01","ids":{"openalex":"https://openalex.org/W4301397367","doi":"https://doi.org/10.1016/j.htct.2022.09.1188"},"language":"en","primary_location":{"id":"doi:10.1016/j.htct.2022.09.1188","doi":"https://doi.org/10.1016/j.htct.2022.09.1188","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2022.09.1188","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137922013128/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.sciencedirect.com/science/article/pii/S2531137922013128/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039052469","display_name":"Valeh Huseynov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Valeh Huseynov","raw_affiliation_strings":["National Hematology and Transfusion Center, Azerbaijan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Hematology and Transfusion Center, Azerbaijan","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5039052469"],"corresponding_institution_ids":[],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":0.2266,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.53837566,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"44","issue":null,"first_page":"S2","last_page":"S3"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.996999979019165},{"id":"https://openalex.org/keywords/transplant-ineligible-patients","display_name":"transplant-ineligible patients","score":0.9900000095367432},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.8529999852180481},{"id":"https://openalex.org/keywords/high-dose-cytarabine","display_name":"high-dose cytarabine","score":0.9350000023841858},{"id":"https://openalex.org/keywords/r-chop","display_name":"R-CHOP","score":0.9449999928474426},{"id":"https://openalex.org/keywords/bendamustine","display_name":"bendamustine","score":0.8529999852180481},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9179999828338623},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.8539999723434448},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.8859999775886536},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6169999837875366},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.4779999852180481},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.48500001430511475},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6309999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.841524600982666},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.8406118154525757},{"id":"https://openalex.org/C2781442060","wikidata":"https://www.wikidata.org/wiki/Q425745","display_name":"Bendamustine","level":4,"score":0.7886176705360413},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6846222281455994},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.6763900518417358},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5669822692871094},{"id":"https://openalex.org/C2779050716","wikidata":"https://www.wikidata.org/wiki/Q4826373","display_name":"Autologous stem-cell transplantation","level":3,"score":0.553818941116333},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.5507956743240356},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4911167323589325},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4742530882358551},{"id":"https://openalex.org/C2779725641","wikidata":"https://www.wikidata.org/wiki/Q1076228","display_name":"CHOP","level":3,"score":0.4290539026260376},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.391865611076355},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.333426296710968},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.31491053104400635},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.27550894021987915},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/j.htct.2022.09.1188","doi":"https://doi.org/10.1016/j.htct.2022.09.1188","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2022.09.1188","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137922013128/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:ec9e6ac530a44015b0bd8d54fb219201","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/ec9e6ac530a44015b0bd8d54fb219201","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hematology, Transfusion and Cell Therapy, Vol 44, Iss , Pp S2-S3 (2022)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.htct.2022.09.1188","doi":"https://doi.org/10.1016/j.htct.2022.09.1188","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2022.09.1188","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137922013128/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4301397367.pdf","grobid_xml":"https://content.openalex.org/works/W4301397367.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2941834455","https://openalex.org/W2740311049","https://openalex.org/W319232779","https://openalex.org/W2029233706","https://openalex.org/W4282913517","https://openalex.org/W1822463313","https://openalex.org/W4252862210","https://openalex.org/W2859240568","https://openalex.org/W2896269241","https://openalex.org/W2024187425"],"abstract_inverted_index":{"MCL":[0,30,186,220,245,267,564],"is":[1,17,31,168,437,453,543,568,585],"a":[2,21,43,169,438,544,554,603],"rare":[3],"but":[4,101],"usually":[5,95],"aggressive":[6,110],"non-Hodgkin":[7],"lymphoma":[8,93,123,148,518,591],"that":[9,443,584],"most":[10],"commonly":[11,163],"affects":[12],"the":[13,52,56,63,79,102,152,157,162,193,232,242,263,285,291,345,358,398,404,465,503,510,607],"elder":[14],"population.":[15],"It":[16],"now":[18],"recognized":[19],"as":[20,235,435],"heterogeneous":[22],"disease":[23,103,411],"with":[24,34,42,90,129,137,143,185,364,515,611],"variable":[25],"biologic":[26],"and":[27,37,68,72,78,84,106,132,154,191,203,222,287,297,336,350,356,374,429,459,471,476,484,495,538,592],"clinical":[28,60,540],"behavior.":[29],"considered":[32],"incurable":[33],"current":[35],"therapies":[36,363],"has":[38,195,214,226,246,268,396],"historically":[39],"been":[40,197,215,227,247],"associated":[41],"poor":[44],"prognosis.":[45],".":[46],"Large":[47],"gains":[48],"were":[49],"made":[50],"in":[51,75,86,231,270,326,341,388,401,425,481,491,502,535,562,588,606],"first":[53],"decade":[54],"of":[55,65,81,141,156,166,244,260,262,266,273,360,367,406,467,512,549,552,597,609],"new":[57,276],"century":[58],"when":[59],"trials":[61],"established":[62],"importance":[64],"high-dose":[66,73,170],"therapy":[67,190,213,601],"autologous":[69,176,332],"stem-cell":[70],"rescue":[71],"cytarabine":[74],"younger":[76,160],"patients":[77,125,136,142,184,221,250,330,407,514,610],"benefits":[80],"maintenance":[82],"rituximab":[83],"bendamustine":[85],"older":[87,133,219],"patients.":[88,240,343],"Patients":[89],"mantle":[91,121,146,390,516,589],"cell":[92,122,147,178,334,391,469,488,517,558,590],"(MCL)":[94,124,149,519],"respond":[96],"to":[97,319,434,446,479,575],"initial":[98],"combination":[99,234,351],"chemotherapy,":[100],"inevitably":[104],"relapses":[105],"often":[107],"follows":[108],"an":[109,271,454,569,582],"course.":[111],"Treatment":[112],"paradigms":[113],"have":[114,378,521],"evolved":[115],"along":[116],"two":[117],"lines.":[118],"Younger,":[119],"fit":[120,135],"are":[126,353,417],"generally":[127,196],"treated":[128],"intensive":[130,189,320],"strategies":[131],"less":[134],"non-intensive":[138],"strategies.":[139],"Management":[140],"newly":[144,182],"diagnosed":[145,183],"depends":[150],"on":[151,505,529],"age":[153],"fitness":[155],"patient.":[158],"For":[159],"patients,":[161],"accepted":[164],"standard":[165],"care":[167],"cytarabine-based":[171],"induction":[172,322],"chemotherapy":[173],"followed":[174,205],"by":[175,206,229,249,284],"stem":[177,333],"transplantation":[179],"(ASCT).":[180],"In":[181,209,256,279,344],"ineligible":[187],"for":[188,218,237,382,423,509],"ASCT,":[192],"standard-of-care":[194],"R-CHOP":[198,233],"(rituximab,":[199],"cyclophosphamide,":[200],"doxorubicin,":[201],"vincristine,":[202],"prednisone),":[204],"rituximab,":[207],"maintenance.":[208],"recent":[210],"years,":[211],"bendamustine-based":[212],"increasingly":[216],"adopted":[217],"more":[223,306,448],"recently,":[224],"vincristine":[225],"replaced":[228],"bortezomib":[230],"VR-CAP":[236],"previously":[238],"untreated":[239],"Traditionally,":[241],"treatment":[243,399,414,466,511,608],"determined":[248],"being":[251,463],"deemed":[252],"\u201ctransplant-eligible\u201d":[253],"or":[254,413],"\u201ctransplant-ineligible\u201d.":[255],"particular,":[257,280],"greater":[258],"depth":[259],"understanding":[261],"molecular":[264],"pathophysiology":[265],"resulted":[269],"explosion":[272],"specifically":[274,574],"targeted":[275],"efficacious":[277],"agents.":[278],"agents":[281,349],"recently":[282],"approved":[283,422],"Food":[286],"Drug":[288],"Administration":[289],"include":[290],"proteasome":[292],"inhibitor":[293,301,386,395,442,548],"bortezomib,":[294],"immunomodulator":[295],"lenalidomide,":[296],"Bruton's":[298],"tyrosine":[299,577],"kinase":[300],"ibrutinib.":[302,451],"Newer":[303],"data":[304],"suggest":[305],"tolerable":[307],"front-line":[308],"therapy,":[309,527],"including":[310,369],"regimens":[311,352],"incorporating":[312],"novel":[313,348,370],"agents,":[314],"may":[315,325],"produce":[316,337],"similar":[317],"outcomes":[318,340,355,384],"historical":[321],"regimens.":[323],"This":[324],"turn":[327],"preclude":[328],"fewer":[329],"from":[331],"transplant":[335],"better":[338],"long-term":[339],"transplant-ineligible":[342],"relapsed/refractory":[346,389],"setting,":[347],"improving":[354,383],"changing":[357],"landscape":[359,400],"treatment.":[361],"New":[362],"distinct":[365],"mechanisms":[366],"action,":[368],"immunotherapeutics,":[371],"antibody-drug":[372],"conjugates,":[373],"non-covalent":[375],"BTK":[376,420,441,480],"inhibitors,":[377],"demonstrated":[379],"great":[380],"potential":[381],"post\u2013BTK":[385],"failure":[387],"lymphoma.":[392],"Although":[393],"cBTK":[394],"transformed":[397],"B-cell":[402,613],"malignancies,":[403],"majority":[405],"will":[408],"eventually":[409],"experience":[410],"progression":[412],"intolerance.":[415],"There":[416],"2":[418],"oral":[419,547],"inhibitors":[421],"use":[424],"relapsed":[426],"MCL:":[427],"ibrutinib":[428],"acalabrutinib.":[430],"Acalabrutinib,":[431],"originally":[432],"referred":[433],"ACP-196,":[436],"novel,":[439],"irreversible":[440,458],"was":[444],"designed":[445],"be":[447],"kinase-selective":[449],"than":[450],"Orelabrutinib":[452],"orally":[455],"administered,":[456],"potent,":[457,546],"highly":[460],"selective":[461],"BTK-inhibitor":[462],"developed":[464],"B":[468,482,487,492],"malignancies":[470],"autoimmune":[472,496],"diseases.":[473,497],"Tirabrutinib":[474],"irreversibly":[475],"covalently":[477],"binds":[478,573],"cells":[483],"inhibits":[485],"aberrant":[486],"receptor":[489,576],"signalling":[490],"cell-related":[493],"cancers":[494],"Zanubrutinib":[498],"received":[499,522],"accelerated":[500],"approval":[501],"USA":[504],"14":[506],"November":[507],"2019":[508],"adult":[513],"who":[520],"at":[523],"least":[524],"one":[525],"prior":[526],"based":[528],"overall":[530],"response":[531],"rate":[532],"(ORR)":[533],"seen":[534],"phase":[536],"II":[537],"I/II":[539],"trials.":[541],"Palbociclib":[542],"specific,":[545],"CDK4/6":[550],"capable":[551],"inducing":[553],"complete,":[555],"prolonged":[556],"G1":[557],"cycle":[559],"arrest":[560],"(pG1)":[561],"Rb+":[563],"cells.":[565],"Zilovertamab":[566],"vedotin":[567],"antibodydrug":[570],"conjugate,":[571],"which":[572],"kinase-like":[578],"orphan":[579],"receptor-1":[580],"(ROR-1),":[581],"oncoprotein":[583],"pathologically":[586],"expressed":[587],"other":[593],"malignancies.":[594,614],"The":[595],"development":[596],"anti-CD19":[598],"CAR":[599],"T-cell":[600],"represents":[602],"major":[604],"advance":[605],"chemorefractory":[612]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-22T09:42:04.148104","created_date":"2022-10-05T00:00:00"}